Biosimilar, Biobetter, and Biosuperior Therapeutic Proteins

Abstract

Therapeutic proteins are therapeutic agents that help patients who desperately need new treatments. Recently, recombinant proteins have been produced and licensed for therapeutic use against a wide range of clinical conditions, including the treatment of autoimmune diseases/inflammation, malignancies, infectionrelated illnesses, hereditary diseases, etc. Biosimilars, biobetters, and biologics can benefit from the patent expiration of drugs or biopharmaceuticals. Biobetters, for instance, are novel medications derived from current drugs and have superior qualities such as increased stability, selectivity, half-life, reduced immunogenicity, and toxicity. Glycosylation is a common modification of proteins, while PEGylation is the favoured option in most clinical trials. Currently, proteinbased treatments have taken center stage in drug research and development, but several challenges must be addressed, including safety, immunogenicity, protein stability, and degradation. We discuss the emerging trends and approaches in different therapeutic protein drug development with the conceivable elements and issues confronted during the development.